Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.

about

Can new chemical therapies improve the management of multiple sclerosis in children?Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study

P2860

Q39024427-BF6DB0DB-D801-4103-A98F-5C9CDC3C22CA Q57807194-222AA049-5C07-4C43-8515-B10CB6579E46

P2860

Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.

Item

http://www.wikidata.org/entity/Q39675286

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Lateral and escalation therapy ...... clerosis: a comparative study.

@en

Lateral and escalation therapy ...... clerosis: a comparative study.

@nl

type

Item

label

Lateral and escalation therapy ...... clerosis: a comparative study.

@en

Lateral and escalation therapy ...... clerosis: a comparative study.

@nl

prefLabel

Lateral and escalation therapy ...... clerosis: a comparative study.

@en

Lateral and escalation therapy ...... clerosis: a comparative study.

@nl

P1476

Lateral and escalation therapy ...... clerosis: a comparative study.

@en

P2093

Aurora Zanghì

http://www.w3.org/2001/XMLSchema#string

Carmela Leone

http://www.w3.org/2001/XMLSchema#string

Emanuele D'Amico

http://www.w3.org/2001/XMLSchema#string

Francesco Patti

http://www.w3.org/2001/XMLSchema#string

Salvatore Lo Fermo

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Personalized medicine in multiple sclerosis: hope or reality?

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

P2888

s00415-016-8207-z

P304

1802-1809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-016-8207-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

263

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27314964

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis

Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.

about

P2860

P2860

Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921